193 related articles for article (PubMed ID: 36077845)
1. Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic Reprogramming.
Yang Y; Peng Z; Flores ER; Kleinerman ES
Cancers (Basel); 2022 Sep; 14(17):. PubMed ID: 36077845
[TBL] [Abstract][Full Text] [Related]
2. IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo.
Venkatanarayan A; Raulji P; Norton W; Chakravarti D; Coarfa C; Su X; Sandur SK; Ramirez MS; Lee J; Kingsley CV; Sananikone EF; Rajapakshe K; Naff K; Parker-Thornburg J; Bankson JA; Tsai KY; Gunaratne PH; Flores ER
Nature; 2015 Jan; 517(7536):626-30. PubMed ID: 25409149
[TBL] [Abstract][Full Text] [Related]
3. Novel therapeutic interventions for p53-altered tumors through manipulation of its family members, p63 and p73.
Venkatanarayan A; Raulji P; Norton W; Flores ER
Cell Cycle; 2016; 15(2):164-71. PubMed ID: 26652033
[TBL] [Abstract][Full Text] [Related]
4. Islet amyloid polypeptide does not suppress pancreatic cancer.
Taylor AJ; Panzhinskiy E; Orban PC; Lynn FC; Schaeffer DF; Johnson JD; Kopp JL; Verchere CB
Mol Metab; 2023 Feb; 68():101667. PubMed ID: 36621763
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effect of adenovirus-mediated p53 family gene transfer on osteosarcoma cell lines.
Oshima Y; Sasaki Y; Negishi H; Idogawa M; Toyota M; Yamashita T; Wada T; Nagoya S; Kawaguchi S; Yamashita T; Tokino T
Cancer Biol Ther; 2007 Jul; 6(7):1058-66. PubMed ID: 17568187
[TBL] [Abstract][Full Text] [Related]
6. Contraction of human brain vascular pericytes in response to islet amyloid polypeptide is reversed by pramlintide.
Nuñez-Diaz C; Pocevičiūtė D; Schultz N; ; Welinder C; Swärd K; Wennström M
Mol Brain; 2023 Feb; 16(1):25. PubMed ID: 36793056
[TBL] [Abstract][Full Text] [Related]
7. Low expression of p63 and p73 in osteosarcoma.
Park HR; Kim YW; Park JH; Maeng YH; Nojima T; Hashimoto H; Park YK
Tumori; 2004; 90(2):239-43. PubMed ID: 15237589
[TBL] [Abstract][Full Text] [Related]
8. One, two, three--p53, p63, p73 and chemosensitivity.
Müller M; Schleithoff ES; Stremmel W; Melino G; Krammer PH; Schilling T
Drug Resist Updat; 2006 Dec; 9(6):288-306. PubMed ID: 17287142
[TBL] [Abstract][Full Text] [Related]
9. P73 functionally replaces p53 in Adriamycin-treated, p53-deficient breast cancer cells.
Vayssade M; Haddada H; Faridoni-Laurens L; Tourpin S; Valent A; Bénard J; Ahomadegbe JC
Int J Cancer; 2005 Oct; 116(6):860-9. PubMed ID: 15849742
[TBL] [Abstract][Full Text] [Related]
10. Glyoxalase II, a detoxifying enzyme of glycolysis byproduct methylglyoxal and a target of p63 and p73, is a pro-survival factor of the p53 family.
Xu Y; Chen X
J Biol Chem; 2006 Sep; 281(36):26702-13. PubMed ID: 16831876
[TBL] [Abstract][Full Text] [Related]
11. P53 family: at the crossroads in cancer therapy.
Alsafadi S; Tourpin S; André F; Vassal G; Ahomadegbe JC
Curr Med Chem; 2009; 16(32):4328-44. PubMed ID: 19754415
[TBL] [Abstract][Full Text] [Related]
12. IAPP and type 1 diabetes: implications for immunity, metabolism and islet transplants.
Denroche HC; Verchere CB
J Mol Endocrinol; 2018 Feb; 60(2):R57-R75. PubMed ID: 29378867
[TBL] [Abstract][Full Text] [Related]
13. Pramlintide regulation of extracellular matrix (ECM) and apoptosis through mitochondrial-dependent pathways in human nucleus pulposus cells.
Wu X; Song Y; Li S; Liu X; Hua W; Wang K; Liu W; Li S; Zhang Y; Shao Z; Yang C
Int J Immunopathol Pharmacol; 2018; 31():394632017747500. PubMed ID: 29256292
[TBL] [Abstract][Full Text] [Related]
14. p63 and p73 in tumor suppression and promotion.
McKeon FD
Cancer Res Treat; 2004 Feb; 36(1):6-12. PubMed ID: 20396560
[TBL] [Abstract][Full Text] [Related]
15. A microRNA-dependent circuit controlling p63/p73 homeostasis: p53 family cross-talk meets therapeutic opportunity.
Ory B; Ellisen LW
Oncotarget; 2011 Mar; 2(3):259-64. PubMed ID: 21436470
[TBL] [Abstract][Full Text] [Related]
16. A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma.
Ory B; Ramsey MR; Wilson C; Vadysirisack DD; Forster N; Rocco JW; Rothenberg SM; Ellisen LW
J Clin Invest; 2011 Feb; 121(2):809-20. PubMed ID: 21293058
[TBL] [Abstract][Full Text] [Related]
17. iASPP inhibits p53-independent apoptosis by inhibiting transcriptional activity of p63/p73 on promoters of proapoptotic genes.
Cai Y; Qiu S; Gao X; Gu SZ; Liu ZJ
Apoptosis; 2012 Aug; 17(8):777-83. PubMed ID: 22538442
[TBL] [Abstract][Full Text] [Related]
18. Expression profiles of p53, p63, and p73 in benign salivary gland tumors.
Weber A; Langhanki L; Schütz A; Gerstner A; Bootz F; Wittekind C; Tannapfel A
Virchows Arch; 2002 Nov; 441(5):428-36. PubMed ID: 12447671
[TBL] [Abstract][Full Text] [Related]
19. Role of the newer p53 family proteins in malignancy.
Irwin MS; Kaelin WG
Apoptosis; 2001; 6(1-2):17-29. PubMed ID: 11321038
[TBL] [Abstract][Full Text] [Related]
20. p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53.
Davison TS; Vagner C; Kaghad M; Ayed A; Caput D; Arrowsmith CH
J Biol Chem; 1999 Jun; 274(26):18709-14. PubMed ID: 10373484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
